The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarkers of response in patients with gastric/gastroesophageal junction adenocarcinoma (GEA) treated with telisotuzumab adizutecan.
 
John Strickler
Stock and Other Ownership Interests - Triumvira Immunologics, Inc
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol Myers Squibb Foundation; Daiichi Sankyo/Astra Zeneca; GE Healthcare; GlaxoSmithKline; Ipsen; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Natera (Inst); Pfizer; Regeneron; Roche/Genentech; Sanofi; Seagen; Taiho Oncology; Takeda
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); Apollo Therapeutics; AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly (Inst); Erasca, Inc (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Lilly (Inst); Novartis; Pfizer; Quanta Therapeutics (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst)
Expert Testimony - Seagen
 
Judith Raimbourg
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Pierre Fabre; Sanofi; Takeda
Research Funding - Takeda
 
François Ghiringhelli
Honoraria - roche
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Roche/Genentech; Roche/Genentech
 
Jonathan Cohen
Honoraria - AstraZeneca; Medison; Roche
Patents, Royalties, Other Intellectual Property - provisional patent application filed
Travel, Accommodations, Expenses - Medison
 
Chiyoe Kitagawa
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; MSD; Ono Yakuhin; Taiho Pharmaceutical
Research Funding - Abbvie; ALX Oncology; Daiichi Sankyo/Astra Zeneca; MSD; Ono Yakuhin; Sanofi
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Moderna Therapeutics; Pfizer; Regeneron; Vertex; West Pharmaceutical
Consulting or Advisory Role - Pliant
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Agenus (Inst); Alkermes (Inst); Alpine Immune Sciences (Inst); ALX Oncology (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Boundless Bio Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); Compugen (Inst); Cullinan Oncology (Inst); Debiopharm Group (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Helsinn Therapeutics (Inst); IgM Biosciences (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Johnson & Johnson/Janssen (Inst); Johnson & Johnson/Janssen (Inst); Jounce Therapeutics (Inst); Kinnate Biopharma (Inst); KLUS Pharma (Inst); KSQ Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Onconova Therapeutics (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); Pliant (Inst); PureTech (Inst); Qualigen Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Theratechnologies (Inst); Tizona Therapeutics, Inc. (Inst); Treadwell Therapeutics (Inst)
 
Ki Hyeong Lee
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Pfizer
Research Funding - Merck
 
Esma Saada-Bouzid
No Relationships to Disclose
 
Bert O'Neil
Consulting or Advisory Role - Amgen
Speakers' Bureau - AstraZeneca
 
Nandini Rudra-Ganguly
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Xizhi (Adam) Luo
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Lisa Roberts-Rapp
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Raluca Predoiu
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Weilong Zhao
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Rui Li
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Zoe Hunter
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Michael Burns
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Martha Blaney
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Yasutoshi Kuboki
Honoraria - Lilly Japan; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Incyte; Janssen Oncology; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Carna Biosciences (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Chugai Pharma; Incyte